新药新型抗癫痫药物苯巴那酯(cenobamate)在美国获批！

Studies have shown that cenobamate has an inhibitory effect on sustained sodium ion currents and has broad-spectrum anticonvulsant activity, effectively inhibiting epilepsy in focal epilepsy models. (cenobamate) can be taken with or without food. It was developed by SK Life Sciences and was approved by the US FDA on November 21, 2019. It is a new tetrazolidinyl carbamate derivative.

Study 017, a multicenter, double-blind, randomized, placebo-controlled trial published in The Lancet Neurology, confirmed that cenobamate is an effective treatment option for adults with uncontrolled focal-onset epilepsy taking 1 to 3 antiepileptic drugs (ASMs). During the 12-week maintenance period, all doses of Xcopri demonstrated significantly higher response rates (percentage of patients with a ≥50% reduction in seizure frequency) compared with placebo. The response rates of the 100 mg/day, 200 mg/day, and 400 mg/day groups were 40%, 56%, and 64% respectively, while the placebo group was 25%. Additionally, during the maintenance period, 4% (not significantly different), 11% and 21% of patients treated with 100 mg, 200 mg, and 400 mg cenobamate, respectively, experienced a 100% reduction in seizure frequency (100% seizure-free), compared with 1% in the placebo group.

Epilepsy, commonly known as "epilepsy" or "epilepsy", is a chronic disease in which brain nerves suddenly discharge abnormally, causing temporary brain dysfunction. About 70% of patients with epilepsy can have their seizures controlled by regular anti-epileptic drug treatment. Currently, SK Biopharmaceuticals believes that cenobamate can be used to treat epilepsy by inhibiting voltage-gated sodium currents to reduce repetitive neuronal discharges. There are currently 6 doses of cenobamate on the market in the United States: 12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: